Compugen to Present at the Oppenheimer 31st Annual Healthcare Conference

Rhea-AI Summary

Compugen Ltd. (NASDAQ: CGEN) announced its participation in the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 10:40 AM ET. The presentation will be available via live webcast on Compugen's website, with an option for replay afterward. Compugen focuses on developing therapeutics for cancer immunotherapy, featuring its lead candidate COM701, which is in a Phase 1 clinical study. The company also has another candidate, COM902, targeting TIGIT, currently in a Phase 1 trial. Compugen operates from Israel and has a presence in South San Francisco, CA.

HOLON, Israel, March 8, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the Oppenheimer 31^st Annual Healthcare Conference (virtual), on Tuesday, March 16, 2021 at 10:40 AM ET.

A live webcast of the presentation will be available on Compugen's website. A replay will be available after the presentation ends.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Compugen's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is in a Phase 1 clinical study. Compugen's therapeutic pipeline also includes early stage immuno-oncology programs focused largely on myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com.

Company contact:
Elana Holzman
Director, Investor Relations and Corporate Communications Compugen Ltd.
Email: ir@cgen.com 
Tel: +972 (3) 765-8124

Investor Relations contact:
Bob Yedid
LifeSci Advisors, LLC
Email: bob@lifesciadvisors.com   
Tel: +1 (646) 597-6989

Media contact:
Josephine Belluardo, Ph.D.
LifeSci Communications 
Email: jo@lifescicomms.com 
Tel: +1 (646) 751-4361

 

View original content:http://www.prnewswire.com/news-releases/compugen-to-present-at-the-oppenheimer-31st-annual-healthcare-conference-301242202.html

SOURCE Compugen Ltd.

FAQ

When is Compugen's presentation at the Oppenheimer Healthcare Conference?

Compugen's presentation is scheduled for March 16, 2021, at 10:40 AM ET.

How can I watch the Compugen presentation?

The presentation will be available via live webcast on Compugen's website, with a replay accessible afterward.

What are the main products in Compugen's pipeline?

Compugen's lead product candidate is COM701, an anti-PVRIG antibody, and COM902, targeting TIGIT, both in Phase 1 clinical studies.

What is the focus of Compugen's research and development?

Compugen specializes in predictive discovery and development of therapeutics for cancer immunotherapy.

Where is Compugen located?

Compugen is headquartered in Israel, with additional offices in South San Francisco, CA.